This research report provides a comprehensive analysis of the Neurometabolic Disorders market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Neurometabolic Disorders market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Neurometabolic Disorders, challenges faced by the industry, and potential opportunities for market players.
The global Neurometabolic Disorders market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Neurometabolic Disorders market presents opportunities for various stakeholders, including Oral, Parenteral. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Neurometabolic Disorders market. Additionally, the growing consumer demand present avenues for market expansion.
The global Neurometabolic Disorders market was valued at US$ 1182.7 million in 2023 and is projected to reach US$ 1631.1 million by 2030, at a CAGR of 4.7% during the forecast period.
The Neurometabolic Disorders Market is driven by the increasing awareness and understanding of rare inherited metabolic disorders that affect the nervous system. These disorders, such as phenylketonuria and lysosomal storage diseases, require specialized treatments and therapies to manage symptoms and improve the quality of life for affected individuals. As advancements in genetics and diagnostics progress, the demand for research, development, and access to therapies and interventions for neurometabolic disorders continues to grow. These therapies often involve enzyme replacement therapy, gene therapy, or small molecule drugs, aiming to address the underlying metabolic abnormalities associated with these conditions. However, a key challenge for this market is the need to overcome the high cost of treatment and ensure that individuals with these rare disorders have equitable access to life-changing therapies. Regulatory approval, early diagnosis, and addressing potential side effects of treatments are ongoing challenges. Additionally, the market faces competition from other rare diseases, necessitating continuous research and efforts to mobilize resources and global commitment to improving the lives of those affected by neurometabolic disorders. Balancing innovation, affordability, and accessibility while addressing the unique challenges of these conditions is vital for the continued growth of the Neurometabolic Disorders Market.
Key Features:
The research report on the Neurometabolic Disorders market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Neurometabolic Disorders market.
Market Overview: The report provides a comprehensive overview of the Neurometabolic Disorders market, including its definition, historical development, and current market size. It covers market segmentation by Type e.g., Gaucher’s Disease, Fabry Disease, region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Neurometabolic Disorders market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Neurometabolic Disorders markets trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Neurometabolic Disorders market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Neurometabolic Disorders market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Neurometabolic Disorders market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Neurometabolic Disorders market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Neurometabolic Disorders, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Neurometabolic Disorders market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Neurometabolic Disorders market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Market segment by Application
Oral
Parenteral
Global Neurometabolic Disorders Market Segment Percentages, By Region and Country, 2023 %
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross
Outline of Major Chapters:
Chapter 1: Introduces the definition of Neurometabolic Disorders, market overview.
Chapter 2: Global Neurometabolic Disorders market size in revenue.
Chapter 3: Detailed analysis of Neurometabolic Disorders company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurometabolic Disorders in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Neurometabolic Disorders Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Neurometabolic Disorders Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Neurometabolic Disorders Overall Market Size
2.1 Global Neurometabolic Disorders Market Size: 2023 VS 2030
2.2 Global Neurometabolic Disorders Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Neurometabolic Disorders Players in Global Market
3.2 Top Global Neurometabolic Disorders Companies Ranked by Revenue
3.3 Global Neurometabolic Disorders Revenue by Companies
3.4 Top 3 and Top 5 Neurometabolic Disorders Companies in Global Market, by Revenue in 2023
3.5 Global Companies Neurometabolic Disorders Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neurometabolic Disorders Players in Global Market
3.6.1 List of Global Tier 1 Neurometabolic Disorders Companies
3.6.2 List of Global Tier 2 and Tier 3 Neurometabolic Disorders Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Neurometabolic Disorders Market Size Markets, 2023 & 2030
4.1.2 Gaucher’s Disease
4.1.3 Fabry Disease
4.1.4 Pompe Disease
4.1.5 Mucopolysaccharidosis VI
4.1.6 Other
4.2 By Type - Global Neurometabolic Disorders Revenue & Forecasts
4.2.1 By Type - Global Neurometabolic Disorders Revenue, 2019-2024
4.2.2 By Type - Global Neurometabolic Disorders Revenue, 2025-2030
4.2.3 By Type - Global Neurometabolic Disorders Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Neurometabolic Disorders Market Size, 2023 & 2030
5.1.2 Oral
5.1.3 Parenteral
5.2 By Application - Global Neurometabolic Disorders Revenue & Forecasts
5.2.1 By Application - Global Neurometabolic Disorders Revenue, 2019-2024
5.2.2 By Application - Global Neurometabolic Disorders Revenue, 2025-2030
5.2.3 By Application - Global Neurometabolic Disorders Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Neurometabolic Disorders Market Size, 2023 & 2030
6.2 By Region - Global Neurometabolic Disorders Revenue & Forecasts
6.2.1 By Region - Global Neurometabolic Disorders Revenue, 2019-2024
6.2.2 By Region - Global Neurometabolic Disorders Revenue, 2025-2030
6.2.3 By Region - Global Neurometabolic Disorders Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Neurometabolic Disorders Revenue, 2019-2030
6.3.2 US Neurometabolic Disorders Market Size, 2019-2030
6.3.3 Canada Neurometabolic Disorders Market Size, 2019-2030
6.3.4 Mexico Neurometabolic Disorders Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Neurometabolic Disorders Revenue, 2019-2030
6.4.2 Germany Neurometabolic Disorders Market Size, 2019-2030
6.4.3 France Neurometabolic Disorders Market Size, 2019-2030
6.4.4 U.K. Neurometabolic Disorders Market Size, 2019-2030
6.4.5 Italy Neurometabolic Disorders Market Size, 2019-2030
6.4.6 Russia Neurometabolic Disorders Market Size, 2019-2030
6.4.7 Nordic Countries Neurometabolic Disorders Market Size, 2019-2030
6.4.8 Benelux Neurometabolic Disorders Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Neurometabolic Disorders Revenue, 2019-2030
6.5.2 China Neurometabolic Disorders Market Size, 2019-2030
6.5.3 Japan Neurometabolic Disorders Market Size, 2019-2030
6.5.4 South Korea Neurometabolic Disorders Market Size, 2019-2030
6.5.5 Southeast Asia Neurometabolic Disorders Market Size, 2019-2030
6.5.6 India Neurometabolic Disorders Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Neurometabolic Disorders Revenue, 2019-2030
6.6.2 Brazil Neurometabolic Disorders Market Size, 2019-2030
6.6.3 Argentina Neurometabolic Disorders Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Neurometabolic Disorders Revenue, 2019-2030
6.7.2 Turkey Neurometabolic Disorders Market Size, 2019-2030
6.7.3 Israel Neurometabolic Disorders Market Size, 2019-2030
6.7.4 Saudi Arabia Neurometabolic Disorders Market Size, 2019-2030
6.7.5 UAE Neurometabolic Disorders Market Size, 2019-2030
7 Neurometabolic Disorders Companies Profiles
7.1 Amicus Therapeutics
7.1.1 Amicus Therapeutics Company Summary
7.1.2 Amicus Therapeutics Business Overview
7.1.3 Amicus Therapeutics Neurometabolic Disorders Major Product Offerings
7.1.4 Amicus Therapeutics Neurometabolic Disorders Revenue in Global Market 2019-2024
7.1.5 Amicus Therapeutics Key News & Latest Developments
7.2 ISU Abxis
7.2.1 ISU Abxis Company Summary
7.2.2 ISU Abxis Business Overview
7.2.3 ISU Abxis Neurometabolic Disorders Major Product Offerings
7.2.4 ISU Abxis Neurometabolic Disorders Revenue in Global Market 2019-2024
7.2.5 ISU Abxis Key News & Latest Developments
7.3 JCR Pharmaceuticals
7.3.1 JCR Pharmaceuticals Company Summary
7.3.2 JCR Pharmaceuticals Business Overview
7.3.3 JCR Pharmaceuticals Neurometabolic Disorders Major Product Offerings
7.3.4 JCR Pharmaceuticals Neurometabolic Disorders Revenue in Global Market 2019-2024
7.3.5 JCR Pharmaceuticals Key News & Latest Developments
7.4 Biosidus
7.4.1 Biosidus Company Summary
7.4.2 Biosidus Business Overview
7.4.3 Biosidus Neurometabolic Disorders Major Product Offerings
7.4.4 Biosidus Neurometabolic Disorders Revenue in Global Market 2019-2024
7.4.5 Biosidus Key News & Latest Developments
7.5 Greenovation Biotech
7.5.1 Greenovation Biotech Company Summary
7.5.2 Greenovation Biotech Business Overview
7.5.3 Greenovation Biotech Neurometabolic Disorders Major Product Offerings
7.5.4 Greenovation Biotech Neurometabolic Disorders Revenue in Global Market 2019-2024
7.5.5 Greenovation Biotech Key News & Latest Developments
7.6 UAB Proforma
7.6.1 UAB Proforma Company Summary
7.6.2 UAB Proforma Business Overview
7.6.3 UAB Proforma Neurometabolic Disorders Major Product Offerings
7.6.4 UAB Proforma Neurometabolic Disorders Revenue in Global Market 2019-2024
7.6.5 UAB Proforma Key News & Latest Developments
7.7 Dong-A Socio Group
7.7.1 Dong-A Socio Group Company Summary
7.7.2 Dong-A Socio Group Business Overview
7.7.3 Dong-A Socio Group Neurometabolic Disorders Major Product Offerings
7.7.4 Dong-A Socio Group Neurometabolic Disorders Revenue in Global Market 2019-2024
7.7.5 Dong-A Socio Group Key News & Latest Developments
7.8 ExSAR Corporation
7.8.1 ExSAR Corporation Company Summary
7.8.2 ExSAR Corporation Business Overview
7.8.3 ExSAR Corporation Neurometabolic Disorders Major Product Offerings
7.8.4 ExSAR Corporation Neurometabolic Disorders Revenue in Global Market 2019-2024
7.8.5 ExSAR Corporation Key News & Latest Developments
7.9 Lixte Biotechnology
7.9.1 Lixte Biotechnology Company Summary
7.9.2 Lixte Biotechnology Business Overview
7.9.3 Lixte Biotechnology Neurometabolic Disorders Major Product Offerings
7.9.4 Lixte Biotechnology Neurometabolic Disorders Revenue in Global Market 2019-2024
7.9.5 Lixte Biotechnology Key News & Latest Developments
7.10 Neuraltus Pharmaceuticals
7.10.1 Neuraltus Pharmaceuticals Company Summary
7.10.2 Neuraltus Pharmaceuticals Business Overview
7.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Major Product Offerings
7.10.4 Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue in Global Market 2019-2024
7.10.5 Neuraltus Pharmaceuticals Key News & Latest Developments
7.11 Protalix
7.11.1 Protalix Company Summary
7.11.2 Protalix Business Overview
7.11.3 Protalix Neurometabolic Disorders Major Product Offerings
7.11.4 Protalix Neurometabolic Disorders Revenue in Global Market 2019-2024
7.11.5 Protalix Key News & Latest Developments
7.12 Pharming Group
7.12.1 Pharming Group Company Summary
7.12.2 Pharming Group Business Overview
7.12.3 Pharming Group Neurometabolic Disorders Major Product Offerings
7.12.4 Pharming Group Neurometabolic Disorders Revenue in Global Market 2019-2024
7.12.5 Pharming Group Key News & Latest Developments
7.13 Protalix BioTherapeutics
7.13.1 Protalix BioTherapeutics Company Summary
7.13.2 Protalix BioTherapeutics Business Overview
7.13.3 Protalix BioTherapeutics Neurometabolic Disorders Major Product Offerings
7.13.4 Protalix BioTherapeutics Neurometabolic Disorders Revenue in Global Market 2019-2024
7.13.5 Protalix BioTherapeutics Key News & Latest Developments
7.14 Amicus
7.14.1 Amicus Company Summary
7.14.2 Amicus Business Overview
7.14.3 Amicus Neurometabolic Disorders Major Product Offerings
7.14.4 Amicus Neurometabolic Disorders Revenue in Global Market 2019-2024
7.14.5 Amicus Key News & Latest Developments
7.15 Biomarin
7.15.1 Biomarin Company Summary
7.15.2 Biomarin Business Overview
7.15.3 Biomarin Neurometabolic Disorders Major Product Offerings
7.15.4 Biomarin Neurometabolic Disorders Revenue in Global Market 2019-2024
7.15.5 Biomarin Key News & Latest Developments
7.16 Genzyme
7.16.1 Genzyme Company Summary
7.16.2 Genzyme Business Overview
7.16.3 Genzyme Neurometabolic Disorders Major Product Offerings
7.16.4 Genzyme Neurometabolic Disorders Revenue in Global Market 2019-2024
7.16.5 Genzyme Key News & Latest Developments
7.17 Shire
7.17.1 Shire Company Summary
7.17.2 Shire Business Overview
7.17.3 Shire Neurometabolic Disorders Major Product Offerings
7.17.4 Shire Neurometabolic Disorders Revenue in Global Market 2019-2024
7.17.5 Shire Key News & Latest Developments
7.18 Greencross
7.18.1 Greencross Company Summary
7.18.2 Greencross Business Overview
7.18.3 Greencross Neurometabolic Disorders Major Product Offerings
7.18.4 Greencross Neurometabolic Disorders Revenue in Global Market 2019-2024
7.18.5 Greencross Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Neurometabolic Disorders Market Opportunities & Trends in Global Market
Table 2. Neurometabolic Disorders Market Drivers in Global Market
Table 3. Neurometabolic Disorders Market Restraints in Global Market
Table 4. Key Players of Neurometabolic Disorders in Global Market
Table 5. Top Neurometabolic Disorders Players in Global Market, Ranking by Revenue 2023
Table 6. Global Neurometabolic Disorders Revenue by Companies, US$, Mn, 2019-2024
Table 7. Global Neurometabolic Disorders Revenue Share by Companies, 2019-2024
Table 8. Global Companies Neurometabolic Disorders Product Type
Table 9. List of Global Tier 1 Neurometabolic Disorders Companies, Revenue US$, Mn in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurometabolic Disorders Companies, Revenue US$, Mn in 2023 and Market Share
Table 11. By Type – Global Neurometabolic Disorders Revenue, US$, Mn, 2023 & 2030
Table 12. By Type - Neurometabolic Disorders Revenue in Global US$, Mn, 2019-2024
Table 13. By Type - Neurometabolic Disorders Revenue in Global US$, Mn, 2025-2030
Table 14. By Application – Global Neurometabolic Disorders Revenue, US$, Mn, 2023 & 2030
Table 15. By Application - Neurometabolic Disorders Revenue in Global US$, Mn, 2019-2024
Table 16. By Application - Neurometabolic Disorders Revenue in Global US$, Mn, 2025-2030
Table 17. By Region – Global Neurometabolic Disorders Revenue, US$, Mn, 2023 & 2030
Table 18. By Region - Global Neurometabolic Disorders Revenue US$, Mn, 2019-2024
Table 19. By Region - Global Neurometabolic Disorders Revenue US$, Mn, 2025-2030
Table 20. By Country - North America Neurometabolic Disorders Revenue, US$, Mn, 2019-2024
Table 21. By Country - North America Neurometabolic Disorders Revenue, US$, Mn, 2025-2030
Table 22. By Country - Europe Neurometabolic Disorders Revenue, US$, Mn, 2019-2024
Table 23. By Country - Europe Neurometabolic Disorders Revenue, US$, Mn, 2025-2030
Table 24. By Region - Asia Neurometabolic Disorders Revenue, US$, Mn, 2019-2024
Table 25. By Region - Asia Neurometabolic Disorders Revenue, US$, Mn, 2025-2030
Table 26. By Country - South America Neurometabolic Disorders Revenue, US$, Mn, 2019-2024
Table 27. By Country - South America Neurometabolic Disorders Revenue, US$, Mn, 2025-2030
Table 28. By Country - Middle East & Africa Neurometabolic Disorders Revenue, US$, Mn, 2019-2024
Table 29. By Country - Middle East & Africa Neurometabolic Disorders Revenue, US$, Mn, 2025-2030
Table 30. Amicus Therapeutics Company Summary
Table 31. Amicus Therapeutics Neurometabolic Disorders Product Offerings
Table 32. Amicus Therapeutics Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 33. Amicus Therapeutics Key News & Latest Developments
Table 34. ISU Abxis Company Summary
Table 35. ISU Abxis Neurometabolic Disorders Product Offerings
Table 36. ISU Abxis Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 37. ISU Abxis Key News & Latest Developments
Table 38. JCR Pharmaceuticals Company Summary
Table 39. JCR Pharmaceuticals Neurometabolic Disorders Product Offerings
Table 40. JCR Pharmaceuticals Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 41. JCR Pharmaceuticals Key News & Latest Developments
Table 42. Biosidus Company Summary
Table 43. Biosidus Neurometabolic Disorders Product Offerings
Table 44. Biosidus Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 45. Biosidus Key News & Latest Developments
Table 46. Greenovation Biotech Company Summary
Table 47. Greenovation Biotech Neurometabolic Disorders Product Offerings
Table 48. Greenovation Biotech Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 49. Greenovation Biotech Key News & Latest Developments
Table 50. UAB Proforma Company Summary
Table 51. UAB Proforma Neurometabolic Disorders Product Offerings
Table 52. UAB Proforma Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 53. UAB Proforma Key News & Latest Developments
Table 54. Dong-A Socio Group Company Summary
Table 55. Dong-A Socio Group Neurometabolic Disorders Product Offerings
Table 56. Dong-A Socio Group Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 57. Dong-A Socio Group Key News & Latest Developments
Table 58. ExSAR Corporation Company Summary
Table 59. ExSAR Corporation Neurometabolic Disorders Product Offerings
Table 60. ExSAR Corporation Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 61. ExSAR Corporation Key News & Latest Developments
Table 62. Lixte Biotechnology Company Summary
Table 63. Lixte Biotechnology Neurometabolic Disorders Product Offerings
Table 64. Lixte Biotechnology Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 65. Lixte Biotechnology Key News & Latest Developments
Table 66. Neuraltus Pharmaceuticals Company Summary
Table 67. Neuraltus Pharmaceuticals Neurometabolic Disorders Product Offerings
Table 68. Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 69. Neuraltus Pharmaceuticals Key News & Latest Developments
Table 70. Protalix Company Summary
Table 71. Protalix Neurometabolic Disorders Product Offerings
Table 72. Protalix Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 73. Protalix Key News & Latest Developments
Table 74. Pharming Group Company Summary
Table 75. Pharming Group Neurometabolic Disorders Product Offerings
Table 76. Pharming Group Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 77. Pharming Group Key News & Latest Developments
Table 78. Protalix BioTherapeutics Company Summary
Table 79. Protalix BioTherapeutics Neurometabolic Disorders Product Offerings
Table 80. Protalix BioTherapeutics Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 81. Protalix BioTherapeutics Key News & Latest Developments
Table 82. Amicus Company Summary
Table 83. Amicus Neurometabolic Disorders Product Offerings
Table 84. Amicus Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 85. Amicus Key News & Latest Developments
Table 86. Biomarin Company Summary
Table 87. Biomarin Neurometabolic Disorders Product Offerings
Table 88. Biomarin Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 89. Biomarin Key News & Latest Developments
Table 90. Genzyme Company Summary
Table 91. Genzyme Neurometabolic Disorders Product Offerings
Table 92. Genzyme Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 93. Genzyme Key News & Latest Developments
Table 94. Shire Company Summary
Table 95. Shire Neurometabolic Disorders Product Offerings
Table 96. Shire Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 97. Shire Key News & Latest Developments
Table 98. Greencross Company Summary
Table 99. Greencross Neurometabolic Disorders Product Offerings
Table 100. Greencross Neurometabolic Disorders Revenue US$, Mn & 2019-2024
Table 101. Greencross Key News & Latest Developments
List of Figures
Figure 1. Neurometabolic Disorders Segment by Type in 2023
Figure 2. Neurometabolic Disorders Segment by Application in 2023
Figure 3. Global Neurometabolic Disorders Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Neurometabolic Disorders Market Size: 2023 VS 2030 US$, Mn
Figure 6. Global Neurometabolic Disorders Revenue, 2019-2030 US$, Mn
Figure 7. The Top 3 and 5 Players Market Share by Neurometabolic Disorders Revenue in 2023
Figure 8. By Type - Global Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 9. By Application - Global Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 10. By Type - Global Neurometabolic Disorders Revenue, US$, Mn, 2023 & 2030
Figure 11. By Type - Global Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 12. By Application - Global Neurometabolic Disorders Revenue, US$, Mn, 2023 & 2030
Figure 13. By Application - Global Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 14. By Region - Global Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 15. By Country - North America Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 16. US Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 17. Canada Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 18. Mexico Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 19. By Country - Europe Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 20. Germany Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 21. France Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 22. U.K. Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 23. Italy Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 24. Russia Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 25. Nordic Countries Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 26. Benelux Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 27. By Region - Asia Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 28. China Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 29. Japan Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 30. South Korea Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 31. Southeast Asia Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 32. India Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 33. By Country - South America Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 34. Brazil Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 35. Argentina Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 36. By Country - Middle East & Africa Neurometabolic Disorders Revenue Market Share, 2019-2030
Figure 37. Turkey Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 38. Israel Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 39. Saudi Arabia Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 40. UAE Neurometabolic Disorders Revenue, US$, Mn, 2019-2030
Figure 41. Amicus Therapeutics Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 42. ISU Abxis Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 43. JCR Pharmaceuticals Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 44. Biosidus Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 45. Greenovation Biotech Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 46. UAB Proforma Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 47. Dong-A Socio Group Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 48. ExSAR Corporation Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 49. Lixte Biotechnology Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 50. Neuraltus Pharmaceuticals Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 51. Protalix Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 52. Pharming Group Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 53. Protalix BioTherapeutics Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 54. Amicus Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 55. Biomarin Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 56. Genzyme Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 57. Shire Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
Figure 58. Greencross Neurometabolic Disorders Revenue Year Over Year Growth US$, Mn & 2019-2024
